Certolizumab

Sanofi's oral TNF inhibitor balinatunfib failed to achieve statistical significance in its primary endpoint (PASI-75) during a Phase II psoriasis trial, despite showing clinically relevant changes.

A new cross-sectional study found that average costs for first-line biologic treatments for plaque psoriasis increased from $21,236 in 2007 to $47,125 in 2021, reflecting a shift toward newer IL-17 and IL-23 inhibitors.

The IMPACT trial demonstrates that certolizumab pegol significantly reduces adverse pregnancy outcomes in women with antiphospholipid syndrome, with complication rates dropping from 69-79% to just 20%.

The FDA issued a complete response letter for UCB's bimekizumab, citing unresolved observations from FDA inspections, delaying potential approval for moderate-to-severe plaque psoriasis.